Stock Update (NYSE:ACT): Eli Lilly loses Alimta drug patent case in Germany to Actavis

[Reuters – UK Focus] – Eli Lilly has lost a patent case in Germany over its blockbuster Alimta lung cancer drug to generic producer Actavis (NYSE: ACT – news) , hitting the U.S. . . . → Read More: Stock Update (NYSE:ACT): Eli Lilly loses Alimta drug patent case in Germany to Actavis Similar Articles: Company Update (NYSE:LLY): Eli Lilly loses Alimta drug patent case in Germany to Actavis Market Update: Gilead Sciences Inc (NASDAQ:GILD) – India rejects Gilead’s Hepatitis C drug patent request Stock Update (NYSE:PFE): FDA panel votes to keep severe warning on Pfizer anti-smoking drug